Company Filing History:
Years Active: 2019
Title: Kevin Richard Sweeney: Innovator in Therapeutic Dosing Regimens
Introduction
Kevin Richard Sweeney is a notable inventor based in East Lyme, Connecticut. He has made significant contributions to the field of medicine, particularly in the treatment of disorders characterized by elevated low-density lipoprotein cholesterol (LDL-C) levels. His innovative approach focuses on therapeutic dosing regimens that utilize anti-PCSK9 antibodies.
Latest Patents
Kevin Richard Sweeney holds a patent for "Treatment with anti-PCSK9 antibodies." This invention relates to therapeutic dosing regimens that employ a dose reduction strategy for treating patients with marked elevations of LDL-C in their plasma. The patent outlines a method of delivering an initial dose of at least about 100 mg of an anti-proprotein convertase subtilisin kexin type 9 (PCSK9) antagonist antibody. Subsequent doses can be administered at the same amount or at least half the initial dose once the patient's LDL-C levels reach specific thresholds.
Career Highlights
Kevin is currently associated with Pfizer Corporation, a leading global pharmaceutical company. His work at Pfizer has allowed him to focus on innovative treatments that address critical health issues. His dedication to research and development has positioned him as a key player in the pharmaceutical industry.
Collaborations
Kevin Richard Sweeney collaborates with Anne Barbara Cropp, contributing to advancements in therapeutic strategies and patient care. Their combined expertise enhances the potential for groundbreaking innovations in the medical field.
Conclusion
Kevin Richard Sweeney's contributions to therapeutic dosing regimens highlight his commitment to improving patient outcomes through innovative treatments. His work continues to influence the landscape of medical therapies, showcasing the importance of research and collaboration in the field.